REAFFIRM trial data shows no significant difference between rotor ablation and conventional therapy

Johannes Brachmann (Coburg, Germany) speaks to Cardiac Rhythm News at HRS 2019 about the REAFFIRM trial, which compared the use of rotor ablation vs. conventional ablation when treating patients with persistent atrial fibrillation.

Brachmann outlines the key findings of the study which found that there was “no significant difference” between FIRM (focal impulse and rotor modulation) guided therapy and conventional therapy. Brachmann notes that there was “a very high success rate in both arms” which “well exceeded” previously recorded results.

Brachmann went on to explain that the best results were achieved with patients undergoing standard PVI (pulmonary vein isolation) plus rotor ablation, but that the data did not prove to be “statistically significant”. “We need to do more studies to further evaluate this very interesting technology”, he said.

Brachmann, Johannes

Professor Brachmann serves as Chief of Cardiology at II. Med. Hospital Klinikum in Coburg. He is a member of scientific committees of the German Cardiac Society, European Society of Cardiology and Heart Rhythm Society. He has more than 300 publications and abstracts.

Professor Brachmann has been the principle investigator of more than 20 clinical studies mostly in the area of cardiac electrophysiology and interventional cardiology. He graduated from the Medical School at the University of Heidelberg.

Add comment

Editor’s Cardiovascular Pick

    Subscribeto receive the very best in medical videos